A new use for B-type natriuretic peptide: to detect myocardial ischaemia in non-heart failure patients

Abstract

B-type natriuretic peptide (BNP) is a natriuretic peptide released primarily by ventricular myocytes in response to various physiological and pathological stimuli. In addition to its established diagnostic role in patients with heart failure, a growing body of evidence suggests that raised levels of BNP in the absence of heart failure can indicate myocardial ischaemia. This appears to be the case in patients with symptomatic, and even asymptomatic coronary artery disease (CAD). In this review, we discuss the current evidence supporting the role of BNP as a simple marker of cardiac ischaemia and CAD. We also propose some therapeutic interventions that may be useful when BNP detects silent myocardial ischaemia.

Keywords

BNP coronary artery disease ischaemic heart disease myocardial ischaemia

Get full access to this article

View all access options for this article.

References

Daniels LB , Maisel AS Natriuretic peptides. J Am Coll Cardiol 2007 ;50:2357-68.

Espiner EA , Richards AM , Yandle TG , Nicholls MG Natriuretic hormones. Endocrinol Metab Clin North Am 1995;24:481-509.

George J. , Struthers AD Natriuretic Peptides. 1st ed. Philadelphia: Mosby Elsevier, 2007;1222.

Nakao K. , Ogawa Y. , Suga S. , Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens 1992;10:1111-14.

Nakagawa O. , Ogawa Y. , Itoh H. et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an ‘emergency’ cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7.

Cowie MR , Jourdain P. , Maisel A. et al. Clinical applications of B-type natriuretic peptide (BNP) testing . Eur Heart J 2003;24:1710-18.

National Institute for Health and Clinical Excellence. NICE Clinical Guideline 5. Chronic Heart Failure. July 2003. www.nice.org.uk (Accessed 1st August 2008).

Scottish Intercollegiate Guidelines Network. SIGN Guideline 95: Management of chronic heart failure. Feb 2007. www.sign.ac.uk (Accessed 1st August 2008).

Wang TJ , Larson MG , Levy D. et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350: 655-63.

10.

McKie PM , Rodeheffer RJ , Cataliotti A. et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006;47:874-80.

11.

Witham MD , Gillespie ND , Hutcheon SD et al. B-type natriuretic peptide is associated with mortality in older functionally impaired patients. J Am Geriatr Soc 2005;53:1991-5.

12.

Kistorp C. , Raymond I. , Pedersen F. et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293:1609-16.

13.

Tarnow L. , Hildebrandt P. , Hansen BV et al. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 2005;48:149-55.

14.

Gaede P. , Hildebrandt P. , Hess G. et al. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria . Diabetologia 2005;48:156-63.

15.

Richards AM , Nicholls MG , Yandle TG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.

16.

Mega JL , Morrow DA , De Lemos JA et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy . J Am Coll Cardiol 2004;44:335-9.

17.

Morrow DA , de Lemos JA , Sabatine MS et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72.

18.

James SK , Lindahl B. , Siegbahn A. et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.

19.

Omland T. , Sabatine MS , Jablonski KA et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007;50:205-14.

20.

Kragelund C. , Gronning B. , Kober L. et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.

21.

Davidson NC , Pringle SD , Pringle TH et al. Right coronary artery stenosis is associated with impaired cardiac endocrine function during exercise. Eur Heart J 1997;18:1749-54.

22.

Bibbins-Domingo K. , Ansari M. , Schiller NB et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study . Circulation 2003;108:2987-92.

23.

Sadanandan S. , Cannon CP , Chekuri K. et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:564-8.

24.

Asada J. , Tsuji H. , Iwasaka T. et al. Usefulness of plasma brain natriuretic peptide levels in predicting dobutamine-induced myocardial ischemia. Am J Cardiol 2004;93:702-04.

25.

Weber M. , Dill T. , Arnold R. et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004;148:612-20.

26.

Goetze JP , Christoffersen C. , Perko M. et al. Increased cardiac BNP expression associated with myocardial ischemia . FASEB J 2003;17: 1105-07.

27.

Rutter MK , Wahid ST , McComb JM , Marshall SM Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 2002; 40:56-61.

28.

de Vreede-Swagemakers JJ , Gorgels AP , Dubois-Arbouw WI et al. Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997;30:1500-05.

29.

Bergeron S. , Moller JE , Bailey KR et al. Exertional changes in circulating cardiac natriuretic peptides in patients with suggested coronary artery disease. J Am Soc Echocardiogr 2006;19:772-6.

30.

Foote RS , Pearlman JD , Siegel AH , Yeo KT Detection of exercise-induced ischemia by changes in B-type natriuretic peptides . J Am Coll Cardiol 2004;44:1980-7.

31.

Tateishi J. , Masutani M. , Ohyanagi M. , Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000;23:776-80.

32.

Kalra PR , Gomma A. , Daly C. et al. Reduction in plasma concentrations of N terminal pro B type natriuretic peptide following percutaneous coronary intervention. Heart 2004;90:1334-5.

33.

McClure SJ , Gall S. , Schechter CB et al. Percutaneous coronary revascularization reduces plasma N-terminal pro-B-type natriuretic peptide concentration in stable coronary artery disease . J Am Coll Cardiol 2007;49:2394-7.

34.

Corrado D. , Basso C. , Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res 2001;50:399-408.

35.

Rana BS , Davies JI , Band MM et al. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart 2006 ;92:916-20.

36.

Wong KY , McSwiggan S. , Kennedy NS et al. B-type natriuretic peptide identifies silent myocardial ischaemia in stroke survivors. Heart 2006;92:487-9.

37.

Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001.